{"url_path":"/sec/ctmx/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1501989/0001193125-26-277631-index.html","accession_number":"0001193125-26-277631","cik":"0001501989","ticker":"CTMX","issuer_name":"CytomX Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501989/0001193125-26-277631-index.html","primary_entity_key":"0001501989","primary_entity_name":"CytomX Therapeutics, Inc."},"word_count":106,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n  \n\nDescription\n\n3.1\n  \n[Certificate of Amendment to Amended and Restated Certificate of Incorporation](d154321dex31.htm)\n\n10.1\n  \n[Amended and Restated CytomX Therapeutics, Inc. 2015 Equity Incentive Plan](d154321dex101.htm)\n\n10.2\n  \n[Amended and Restated CytomX Therapeutics, Inc. Employee Stock Purchase Plan](d154321dex102.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \nCYTOMX THERAPEUTICS, INC.\n\nDate: June 22, 2026\n \n\n \nBy:\n \n\n/s/ Christopher W. Ogden\n\n \n\n \n\n \nChristopher W. Ogden\n\n \n\n \n\n \nSVP, Chief Financial Officer"}